AGP Picks
View all

Technology Review Mississippi: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Review Mississippi.

Press releases published on August 6, 2026

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
SEO Migration Risk: 4,000 AI Answers Tie 20-40% Traffic Loss to Execution
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
Sionna Therapeutics Reports Second Quarter 2026 Financial Results
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
Harrow Acquires Global Rights to TYRVAYA®,  the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
illumin Reports Second Quarter 2026 Financial Results
Verano Announces Upcoming Conference Participation
CareCloud Reports Second Quarter 2026 Results
Commerce Announces Second Quarter 2026 Financial Results
GPGI Reports Second Quarter 2026 Results
Lantheus Reports Second Quarter 2026 Financial Results
Tilray Brands Expands THC Beverage Innovation with the Launch of Mollo Lite Blackberry Lemon Seltzer Multi-Pack
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Datadog Announces Second Quarter 2026 Financial Results
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Technology Review Mississippi

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.